Integral Health Asset Management LLC Takes $3.18 Million Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Integral Health Asset Management LLC bought a new position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 1,050,000 shares of the company's stock, valued at approximately $3,182,000. Integral Health Asset Management LLC owned 1.47% of Zentalis Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZNTL. Almitas Capital LLC lifted its stake in Zentalis Pharmaceuticals by 69.3% in the 4th quarter. Almitas Capital LLC now owns 1,626,896 shares of the company's stock valued at $4,929,000 after buying an additional 665,968 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of Zentalis Pharmaceuticals by 1.5% during the 4th quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company's stock worth $4,608,000 after buying an additional 22,600 shares during the last quarter. Geode Capital Management LLC increased its holdings in Zentalis Pharmaceuticals by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company's stock valued at $3,979,000 after purchasing an additional 20,864 shares in the last quarter. D. E. Shaw & Co. Inc. increased its holdings in Zentalis Pharmaceuticals by 9.8% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,239,459 shares of the company's stock valued at $3,756,000 after purchasing an additional 110,882 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Zentalis Pharmaceuticals by 75.7% in the 4th quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company's stock valued at $2,605,000 after buying an additional 370,511 shares during the last quarter.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL remained flat at $1.26 during trading hours on Friday. 410,314 shares of the stock traded hands, compared to its average volume of 1,555,389. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.01 and a 52 week high of $13.00. The business's fifty day simple moving average is $1.44 and its 200-day simple moving average is $2.33. The company has a market capitalization of $90.66 million, a price-to-earnings ratio of -0.51 and a beta of 1.81.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.67). As a group, equities analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on ZNTL. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday. Wells Fargo & Company decreased their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. Wedbush reissued a "neutral" rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday. Finally, UBS Group lowered their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $8.24.

Insider Activity at Zentalis Pharmaceuticals

In other news, Director Scott Dunseth Myers purchased 21,000 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was bought at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the acquisition, the director now directly owns 281,192 shares of the company's stock, valued at $393,668.80. This represents a 8.07% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.90% of the stock is owned by corporate insiders.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.